拍张眼睛照能查肝胆疾病?专家说肝癌、肝硬化精准度高达9成

2021-01-29 39健康网 39健康网

眼睛不仅是“心灵的窗户”,也可以是“健康的窗口”。眼睛作为一个体表器官,全身唯一可以直接观察到神经组织和动静脉的“窗口”,全身很多器官系统的病理变化,都会在眼睛留下“痕迹”。

很多人不清楚,身体健康状况变化,最早会在眼睛里露出“端倪”,作为全身唯一可以看到静脉、动脉和神经(视神经)的地方,眼睛已被研究证实是多种疾病的早期发现“窗口”。近日,中山大学眼科中心和中山大学附属第三医院共同领衔,首次研发出通过眼部影响筛诊肝胆疾病的技术及评估系统,林浩添教授表示,只需将眼表或眼底的照片传至系统平台,不到一分钟就可筛查出是否患有肝胆疾病,甚至可帮助诊断,是全球首个通过眼部影像筛诊肝胆疾病的智能技术

39健康了解,2021年1月26日在国际顶级期刊《The Lancet Digital Health》发表,被喻为是人工智能技术引导了不同学科的合作创新,并产生了新时代的医疗技术。

肝胆疾病可通过眼部特征改变

现实生活中,一个人出现肝炎或者肝癌时,眼睛总会有黄染的现象出现,而传统医学也已经证实,肝胆疾病患者可出现结膜和巩膜黄染等多种临床体征,然而由于传统医疗的局限性,仅有少数患者和严重病例的眼部特征改变被临床医师发现和应用,无法进行技术发掘和大规模人群筛查。

林浩添介绍,其实相对于其他器官部位,以眼为窗口进行全身智能健康管理具有多项优势。首先,眼部数据最易于采集、模态最为丰富,眼科也成为人工智能应用的领跑学科,为人工智能在其他多个医学领域发展提供丰富经验。

与此同时,中国又是“肝病大国”,有近4亿肝病患者,约占全世界肝病患者总人数的三分之一。现有的检查方法如血检等有创检查或B超、CT、MRI等影像学技术不足以满足大规模人群的筛诊需求。

“如果能够将两者相结合,通过非侵入性诊断测试来筛查肝胆疾病患者并评估其治疗资格,对整个人群都是有益的。”林浩添指出,为此早在2018年即提出要以眼睛为窗口创建疾病新管理模式的概念,通过近三年的探索与布局,使智能模型通过一站式眼科检查识别全身病成为可能,进一步实现对疾病的预防、筛查、诊疗、随访的统一管理。

The Lancet DigitalHealth在线发表文章页面

新系统可筛查6种常见肝胆疾病,肝癌诊断精确率高达9成

据悉,该研究纳入来自中山大学附属第三医院肝胆外科及感染科、南方医科大学附属花都区人民医院感染科、爱康集团广州爱康国宾检查中心南天分院及环市分院这五个医疗机构的1789名参与者,通过前瞻性采集他们眼表及眼底影像学数据,研究组使用深度学习技术成功地从这些影像数据中提取出肝胆疾病的眼部特征并开发及验证了14个模型(7个裂隙灯模型及7个眼底模型)。

分别用于筛查是否患有肝胆疾病及诊断是否患有肝癌、肝硬化、慢性病毒性肝炎、非酒精性脂肪肝、胆石症及肝囊肿六大类常见肝胆疾病。

“目前肝癌、肝硬化的诊断率高达9成,而在症状相对较轻的慢性病毒性肝炎、非酒精性脂肪肝、胆石症及肝囊肿中则表现欠佳。” 林浩添指出,后续将会将此系统部署在中山大学中山眼科中心智能诊断预测云平台上,可作为大规模快速无创筛诊的工具。

“这个技术目前是从0到1的一个过程,”,林浩添表示,下一步将继续扩大研究的样本量,并进行技术上的完善,“下一步是从1到N,我们的最终目标是希望市民可在家中用自己的手机拍下眼部照片后上传至平台,即可轻松诊断出是否患有肝胆疾病”。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-30 ms2000001255765209

    期待普及

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-30 carrotlyl

    期待

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 guging

    谢谢!最新的信息读起来就是收获大

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1403545, encodeId=41181403545d7, content=<a href='/topic/show?id=ebbde6353be' target=_blank style='color:#2F92EE;'>#精准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76353, encryptionId=ebbde6353be, topicName=精准)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epQX9hfEIBiaPg0e9KvLYVBCSGYydH6K6OQxBh3RaOC0TYP9HYy2v0XdHib1LFnZNU5Siak0P8oh8Aqw/132, createdBy=acd92440184, createdName=shijzhiewnjhch, createdTime=Sun Jan 31 10:32:07 CST 2021, time=2021-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921272, encodeId=cbaa9212e244, content=期待普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5bf5452198, createdName=ms2000001255765209, createdTime=Sat Jan 30 09:26:08 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921253, encodeId=0acf921253c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Sat Jan 30 05:58:07 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040350, encodeId=234b104035011, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046476, encodeId=752e10464e688, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Jan 29 22:32:07 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921201, encodeId=2c18921201de, content=文章呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200810/413f8b33b4e34dcd82cbfc3ffd0f8c3c/4393e48ea913472084d5677670d3b48b.jpg, createdBy=b52c5409947, createdName=WL, createdTime=Fri Jan 29 20:56:10 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 WL

    文章呢

    0